Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

NCT07729397 is registered in ClinicalTrials.gov with The Methodist Hospital Research Institute as lead sponsor.

NCT NCT07729397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07729397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)
Lead sponsor
The Methodist Hospital Research Institute
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 15, 2027
Completion date
February 28, 2044
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, alk-negative, anaplastic large cell lymphoma, alk-positive, diffuse large b-cell lymphoma (dlbcl), hodgkin lymphoma, peripheral t-cell lymphoma (ptcl)